Biological Therapies for Rheumatoid Arthritis: Progress to Date

被引：0
作者：
Gaurav Malviya
Simonetta Salemi
Bruno Laganà
Andrea Picchianti Diamanti
Raffaele D’Amelio
Alberto Signore
机构：
[1] University Medical Centre Groningen,Department of Nuclear Medicine and Molecular Imaging
[2] University of Groningen,Nuclear Medicine Department, Faculty of Medicine and Psychology
[3] “Sapienza” University of Rome,Clinical Immunology and Rheumatology Unit, Faculty of Medicine and Psychology
[4] St. Andrea Hospital,undefined
[5] “Sapienza” University of Rome,undefined
来源：
BioDrugs | 2013年 / 27卷
关键词：
Rheumatoid Arthritis; Infliximab; Rheumatoid Arthritis Patient; Etanercept; Adalimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Biologic drugs for the management of rheumatoid arthritis (RA) have revolutionized the therapeutic armamentarium with the development of several novel monoclonal antibodies, which include murine, chimeric, humanized, fully human antibodies and fusion proteins. These biologics bind to their targets with high affinity and specificity. Since 1998, nine different biologics have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of RA, and several others are in different stages of clinical trials. This field is in continuous evolution and new biologics are tested every year. Therefore a precise analysis is required in order to have a detailed and updated state of the art of this field. In this review, our main aim is to analyse all available biological therapies that are FDA and EMA approved for the treatment of RA and also those that are in clinical trials for the management of RA patients.
引用
收藏
页码：329 / 345
页数：16
相关论文
共 651 条
[1]  
Doran MF(2002)Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum 46 2287-2293
[2]  
Crowson CS(1998)Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study BMJ 317 180-181
[3]  
Pond GR(2003)Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 1303-1307
[4]  
O’Fallon WM(2003)Increase in cardiovascular disease prevalence in rheumatoid arthritis J Rheumatol 30 36-40
[5]  
Gabriel SE(2000)Risk of malignancy among patients with rheumatic conditions Int J Cancer 88 497-502
[6]  
Baecklund E(2009)Cardiovascular disease is associated with extra-articular manifestations in patients with rheumatoid arthritis Clin Rheumatol 28 767-775
[7]  
Ekbom A(2002)Rheumatoid arthritis association in Colombian population is restricted to HLA-DRB1*04 QRRAA alleles Genes Immun 3 56-68
[8]  
Sparen P(1994)The mortality of rheumatoid arthritis Arthritis Rheum 37 481-494
[9]  
Feltelius N(2007)Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischemic heart disease and in pulmonary fibrosis Rheumatology 46 350-357
[10]  
Klareskog L(2003)Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years Arthritis Rheum 48 54-58
12345678910